LKT Labs

Biochemicals for Life Science Research

AZD-7762 Hydrochloride

AZD-7762 Hydrochloride

Product ID A9912
Cas No. 1246094-78-9
Purity ≥98%
Product Unit SizeCostQuantityStock
1 mg $102.00 In stock
5 mg $177.00 In stock
10 mg $279.00 In stock
Bulk Quote

Quicklinks

Description

AZD-7762 is an inhibitor of checkpoint kinase (CHK) 1 that increases sensitivity to DNA-damaging compounds. AZD-7762 exhibits anticancer chemotherapeutic activity and is currently in clinical trials as a potential treatment for a variety of cancers. In breast cancer and ovarian cancer cells, AZD-7762 inhibits cellular proliferation. In animal models of breast cancer, AZD-7762 inhibits tumor growth and increases survival rates. This compound displays somewhat limited efficacy due to cardiac toxicity.

Product Info

Cas No.

1246094-78-9
Purity

≥98%
Formula

C17H19FN4O2S • HCl
Formula Wt.

398.88
IUPAC Name

3-(carbamoylamino)-5-(3-fluorophenyl)-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide;hydrochloride
Synonym

AZD-7762 HCl
Solubility

DMSO 50 mg/mL (137.96 mM) Water Insoluble Ethanol Insoluble
Appearance

White to off white powder

Shipping and Storage

Store Temp

-20°C
Ship Temp

Ambient

Downloads

MSDS

A9912 MSDS PDF
Info Sheet

A9912 Info Sheet PDF

References

Bryant C, Rawlinson R, Massey AJ. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers. BMC Cancer. 2014 Aug 7;14:570. PMID: 25104095.

Sausville E, Lorusso P, Carducci M, et al. Phase I dose-escalation study of AZD7762, a checkpoint kinase inhibitor, in combination with gemcitabine in US patients with advanced solid tumors. Cancer Chemother Pharmacol. 2014 Mar;73(3):539-49. PMID: 24448638.

Ma CX, Cai S, Li S, et al. Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest. 2012 Apr;122(4):1541-52. Erratum in: J Clin Invest. 2012 Jul 2;122(7):2702. PMID: 22446188.

Custom Order

  • Size of single unit expressed as number (e.g. '500' in the case of 500 mg)
  • Total quantity of unit size desired (e.g. '10' in the case of 10 x 500 mg). If only one unit is desired, you may leave this blank.
  • This field is for validation purposes and should be left unchanged.

Related Products

  • C5260

    C-type Natriuretic Peptide (1-22), pig/human/rat

    Endogenous cardiomodulatory peptide; NPR-B agon...

    ≥95%
  • B560000

    RAD51 inhibitor, B02

    RAD51 inhibitor.

    ≥98%
  • M1978

    S-(+)-Methoprene

    Juvenille insect growth hormone analog.

    ≥95%
  • A8070

    Auraptene

    Monoterpene coumarin ether found in Citrus; PPA...

    ≥98%
  • A0102

    A23187 Ca-Mg

    Ca2+ ionophore.

    ≥98%, TLC
  • E7731

    17-α-Ethynylestradiol

    Synthetic steroid hormone; ER agonist.

    ≥99%
  • R2516

    RGES

    Peptide, used as control to measure RGDS peptid...

    ≥95%
  • I088240

    (S,S)-ICG-001

    Wnt/β-catenin inhibitor

    ≥98%
  • E5477

    Entinostat

    Benzamide; HDAC1 inhibitor.

    ≥98%
  • B3472

    4,4′-(1,1′-Biphenyl-4,4′-diyldioxy)dianiline

    Potential VEGFR2, Met, RET, Axl, Ron, PDGFR, FG...

    ≥98%
  • N8760

    NVP-TAE684

    ALK, c-Fes, LRRK2 inhibitor.

    ≥98%
  • N0263

    Naphazoline Nitrate

    α1-adrenergic agonist.

    ≥97%
  • D604080

    DpC

    Anti-metastatic

    ≥99%
  • F4681

    Flumazenil

    GABA-A antagonist.

    ≥98%
  • C1627

    Cefaclor Monohydrate

    β-lactam cephalosporin; penicillin binding pro...

    ≥97%
  • P2919

    L-Phenylalaninol

    Non-essential amino acid alcohol.

    ≥98%
  • L9800

    LY-364947

    ALK5 (activin-like) inhibitor.

    ≥98%
  • A0002

    A66

    p110α PI3K inhibitor.

    ≥98%
  • R0154

    Ranolazine Dihydrochloride

    Nav1.7 and Nav1.8 N1+ channel blocker.

    ≥98%
  • M3232

    Methylisoindigotin

    Indirubin derivative.

    ≥98%